Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05054400 | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | withdrawn | Early Phase 1 | 0 | Emory UniversityOTHER | 0 | Dec 2, 2022 | clinicaltrials |
| NCT04776980 |
| Multimodality MRI and Liquid Biopsy in GBM |
| withdrawn |
| Early Phase 1 |
| 0 |
| Abramson Cancer Center at Penn MedicineOTHER |
| 1 |
| Sep 16, 2022 |
| clinicaltrials |
| NCT01331616 | Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab | withdrawn | Early Phase 1 | 0 | West Penn Allegheny Health SystemOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT03980249 | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | withdrawn | Early Phase 1 | 0 | West Virginia UniversityOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | withdrawn | Early Phase 1 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2023source: clinicaltrials